RxPG News : Psychoses

Brain recruiting pattern incorrect in Schizophrenic patients

Wed, 12 Mar 2008 05:38:25 PST

The enduring memory problems that people with schizophrenia experience may be related to differences in how their brains process information, new research has found. The Public Library of Science published the report by Vanderbilt University researchers Junghee Lee, Bradley S. Folley, John Gore and Sohee Park in the online journal PLOS One March 12.

Schizophrenia Risk Gene DISC1 Plays a Broader Role in the Development of Nervous System

Mon, 10 Sep 2007 04:19:08 PST

How the gene that has been pegged as a major risk factor for schizophrenia and other mood disorders that affect millions of Americans contributes to these diseases remains unclear. However, the results of a new study by Hopkins researchers and their colleagues, appearing in Cell this week, provide a big clue by showing what this gene does in normal adult brains.

First genome-wide study revealed genetic roots of bipolar illness

Wed, 23 May 2007 04:00:00 PST

The likelihood of developing bipolar disorder depends in part on the combined, small effects of variations in many different genes in the brain, none of which is powerful enough to cause the disease by itself, a new study shows. However, targeting the enzyme produced by one of these genes could lead to development of new, more effective medications. The research was conducted by scientists at the National Institutes of Health's National Institute of Mental Health (NIMH), with others from the Universities of Heidelberg and Bonn and a number of U.S. facilities collaborating in a major project called the NIMH Genetics Initiative.

Chemical maps hint at drug's effects on schizophrenia

Tue, 15 May 2007 19:16:49 PST

Antipsychotic drugs do most of their work in the brain, but they also leave behind in the bloodstream a trail of hundreds of chemicals that may be used in the future to direct better treatment for schizophrenia and other psychiatric conditions, say Duke University Medical Center researchers.

Diagnosis of Major Depression Might Mask Bipolar illness

Wed, 09 May 2007 08:32:37 PST

Approximately 4.4 percent of U.S. adults may have some form of bipolar disorder during some point in their lifetime, including about 2.4 percent with a "sub-threshold" condition, according to an article in the May issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

Intensive psychotherapy more effective than brief therapy for treating bipolar depression

Tue, 03 Apr 2007 03:09:24 PST

Patients taking medications to treat bipolar disorder are more likely to get well faster and stay well if they receive intensive psychotherapy, according to results from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), funded by the National Institutes of Healthâs (NIH) National Institute of Mental Health (NIMH). The results are published in the April 2007 issue of the Archives of General Psychiatry.

Study challenges idea that schizophrenia is distinct in developing and developed regions

Wed, 14 Mar 2007 08:38:10 PST

Research by the World Health Organization (WHO) has suggested that the course and symptomatic expression of schizophrenia is relatively more benign in developing societies. However, a new study from Current Anthropology challenges this assumption, comparing biological and cultural indicators of schizophrenia in urban, Western societies with study data from the island of Palau, which has one of the highest rates of schizophrenia diagnosis in the world today.

New CATIE Analyses Offer Guidance for Choosing Second-Generation Antipsychotic Medication

Wed, 07 Mar 2007 15:20:04 PST

For patients with chronic schizophrenia who switched from perphenazine to a second-generation antipsychotic, quetiapine and olanzapine were more effective than risperidone. Perphenazine, a first-generation antipsychotic drug, showed effects comparable to most newer drugs in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, but many patients eventually switched because of problems with limited effectiveness or poor tolerability.

New details in schizophrenia treatment trial emerge

Thu, 01 Mar 2007 05:52:59 PST

Two new studies from the Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE) provide more insights into comparing treatment options, and to what extent antipsychotic medications help people with schizophrenia learn social, interpersonal and community living skills. The new studies are published in the March 2007 issue of the American Journal of Psychiatry. CATIE, a $42.6 million, multi-site study, was funded by the National Institutes of Healths National Institute of Mental Health (NIMH).

Abnormalities in eye movements and attention can predict risk of Schizophrenia

Wed, 21 Feb 2007 05:57:56 PST

A Binghamton University researcher has established a new framework to help determine whether individuals might be at risk for schizophrenia.

Possible genetic link to schizophrenia identified

Fri, 09 Feb 2007 02:53:10 PST

Several neurological and psychiatric disorders, including schizophrenia, alcoholism, and Parkinsons disease, are associated with changes in the brain that affect the nerves that communicate with each other through the naturally-produced chemical dopamine. One protein that is crucial for dopamine-mediated neuronal communication in animals is DARPP-32. However, very little is known about the function of this protein in humans.

Brain scan may help doctors predict schizophrenia

Thu, 07 Dec 2006 18:48:57 PST

London, Dec 7 - Brain scans may help doctors predict schizophrenia, a mental disorder that affects one percent of people across the world, says a new study.

People from broken homes prone to psychotic illnesses

Wed, 22 Nov 2006 18:51:00 PST

London, Nov 22 (IANS) People whose parents had separated in childhood could face an increased risk of developing psychotic illnesses than common people, says a new study.

Second-generation antipsychotic medications appear to offer little advantage

Tue, 10 Oct 2006 12:14:00 PST

Among patients with schizophrenia whose medication is changed because of ineffectiveness or harmful side effects, second-generation antipsychotic drugs do not appear to offer significant benefits compared to first-generation antipsychotic drugs, according to a report in the October issue of Archives of General Psychiatry, one of the JAMA/Archives journals. The findings run contrary to the widely held perception that second-generation antipsychotic agents are safer and more effective in treating patients with schizophrenia than the less-expensive first-generation class of medications.

Study aims to identify schizophrenics at risk for type 2 diabetes

Tue, 22 Aug 2006 20:16:00 PST

Dissecting the relationship between schizophrenia and an increased risk of type 2 diabetes has physician-scientists reaching across the Atlantic Ocean.

New Treatment Model for Bipolar Disorder Shows Promise

Fri, 11 Aug 2006 20:09:00 PST

A new care model for bipolar disorder tested in veterans across the nation reduced their manic episodes and improved their quality of life, according to research led by a psychiatrist with the Providence Veterans Affairs Medical Center and Brown Medical School.

Effects of ketamine mimic only some of the symptoms of schizophrenia

Wed, 09 Aug 2006 12:37:00 PST

Ketamine can induce symptoms of referential thinking, but not other symptoms of schizophrenia, according to a new study. Ketamine is the structural analogue of the drug phencyclidine, now considered too toxic for experimental use in humans. In healthy volunteers, phencyclidine has been reported to induce paranoia, perceptual changes and other symptoms, including disorganisation of thought, negativism, apathy, withdrawal, poverty of speech and catatonia.

Association between famine and schizophrenia may yield clues about genetic basis

Wed, 02 Aug 2006 11:33:00 PST

The higher risk of schizophrenia among offspring of expectant mothers living through famine could help us understand the genetic basis for that debilitating mental disorder, a group of researchers argue in a commentary piece in the Aug. 2 issue of JAMA. The finding also supports a theory of medical genetics in which diseases and conditions can be caused by hundreds of different genetic mutations in any number of human genes.

Neuropeptide S (NPS) may help in treating schizophrenia

Mon, 10 Jul 2006 06:18:00 PST

A small protein in the brain that has only recently been discovered and, paradoxically, induces both profound wakefulness and a less anxious state, may represent a novel target for the treatment of psychotic behavior and schizophrenia, according to new research presented at the 6th International Congress of Neuroendocrinology (ICN 2006) recently.

Clozapine causes significantly higher rates of metabolic syndrome

Sat, 01 Jul 2006 16:37:00 PST

Patients who take clozapine, the most effective antipsychotic drug, have significantly higher rates of metabolic syndrome, according to a first-of-a-kind study by University of Rochester Medical Center researchers. Metabolic syndrome is a group of conditions that increase the risk for heart disease, stroke and diabetes. The conditions include high blood pressure, excess body fat around the waist, abnormal levels of cholesterol and triglycerides and insulin resistance. Any one of the conditions increases the risk of serious disease. In combination, the risk grows greater.

Neuropeptide S (NPS) may help in treating schizophrenia

Thu, 22 Jun 2006 23:41:00 PST

NMDA receptor hypofunction demonstrated in schizophrenia

Mon, 19 Jun 2006 01:26:00 PST

Researchers at the University of Pennsylvania School of Medicine, in collaboration with scientists at the City University of New York, have identified a striking dysregulation in neuronal receptor activity in the postmortem brain tissue from patients with schizophrenia. By stimulating receptors in the prefrontal cortex, the research team tracked heightened levels of erbB4 receptor activity, as well as decreased NMDA receptor activity in the tissue from patients with schizophrenia. Additionally, they were able to identify a relationship between these two receptor groups, suggesting a mechanism for decreased NMDA receptor function that has long been suspected in schizophrenia.

Altered NRG1-erbB4 signaling may contribute to NMDA receptor hypofunction in schizophrenia

Fri, 16 Jun 2006 23:59:00 PST

Transcription factor Elk-1's role in neurodegeneration and schizophrenia

Thu, 08 Jun 2006 06:10:00 PST

Researchers at the University of Pennsylvania School of Medicine discovered that a protein called Elk-1 interacts with mitochondria, the energy storehouse of a cell, suggesting that this protein - typically active in the nucleus -- could play a role in cell death and mitochondria-related diseases such as neurodegeneration and schizophrenia.

Youth with bipolar disorder misread facial expressions as hostile

Tue, 30 May 2006 23:23:00 PST

Youth with bipolar disorder misread facial expressions as hostile and show heightened neural reactions when they focus on emotional aspects of neutral faces, researchers at the National Institutes of Health's (NIH) National Institute of Mental Health (NIMH) have discovered. The study provides some of the first clues to the underlying workings of the episodes of mania and depression that disrupt friendships, school, and family life in up to one percent of children.

Schizophrenia limits one's ability to perceive body language

Fri, 19 May 2006 19:50:00 PST

Understanding the meaning behind a person's posture or body movement comes easily to many people and helps guide how we react to others socially.

Hospitalized schizophrenics are at a higher risk for developing medical/surgical complications

Sun, 19 Mar 2006 02:30:00 PST

A Johns Hopkins study of more than 1,700 patients with schizophrenia hospitalized for medical or surgical care unrelated to their mental disorder shows they are at least twice as likely as similar patients without schizophrenia to suffer dangerous and expensive adverse events. The adverse events are associated with poor outcomes, including death.
The researchers concluded that decreased quality of care given to patients with schizophrenia may put them at higher risk for serious infections and other complications.

Transcranial magnetic stimulation to curtail auditory hallucinations in schizophrenia

Sun, 12 Mar 2006 03:53:00 PST

Yale School of Medicine researchers are recruiting patients nationally for a clinical trial using transcranial magnetic stimulation (TMS) to help still the voices that are so troubling to some persons with schizophrenia.

Brain Changes Indicating Bipolar Disorder Are Not Prominent Until Adulthood

Tue, 31 Jan 2006 19:16:00 PST

Changes in the brain that are important indicators of bipolar disorder are not prominent until young adulthood and are reduced in persons taking mood-stabilizing medications, Yale School of Medicine researchers report this month in Biological Psychiatry.

Early Intervention Services in Psychosis Can Achieve Better Outcomes - Study

Mon, 23 Jan 2006 17:14:00 PST

A new study has found that specialised care for early psychosis can achieve better outcomes than standard care.

Manic-depressive illness and the FAT gene

Fri, 13 Jan 2006 20:26:00 PST

A collaboration, led by Sydney scientists at the Garvan Institute of Medical Research and University of New South Wales, has discovered the first risk gene specifically for bipolar disorder, also known as manic-depressive illness. This means that people who have a particular form of this gene are twice as likely to develop the disease.

One in five teens needing inpatient psychiatric care may be manic-depressive

Wed, 28 Dec 2005 18:31:00 PST

Clinicians at Bradley Hospital, the nation's first psychiatric hospital for children and adolescents, have found that bipolar disorder is more common than expected in teens in a psychiatric inpatient setting.

Psychosocial Disability Fluctuates Along with Bipolar Symptoms

Thu, 08 Dec 2005 15:24:00 PST

With every increase or decrease in depressive symptom severity, there is a corresponding significant and stepwise increase or decrease in psychosocial disability among patients with bipolar disorder, according to a study in the December issue of Archives of General Psychiatry, one of the JAMA/Archives journals. Bipolar disorder is characterized by cycles of depression and abnormal elation, or mania. It has been found to be associated with increased suicidal behavior, increased health care use and costs, higher unemployment, higher dependence on public assistance, lower annual income, increased work absenteeism owing to illness, decreased work productivity, poorer overall functioning, lower quality of life, and decreased life span, according to background information in the article. Bipolar I disorder (BP-I), which includes episodes of mania, and bipolar II disorder (BP-II), which includes less severe episodes of abnormal mood elevation called hypomania, are dimensional illnesses in which patients experience fluctuating levels of severity of manic and depressive symptoms, interspersed with symptom-free periods.

Loss of PRODH and COMT gene activity linked to schizophrenia

Fri, 02 Dec 2005 19:04:00 PST

Disruption of the normal interaction between the genes PRODH and COMT contributes directly to major symptoms of schizophrenia by upsetting the balance of the brain chemicals glutamate and dopamine, according to a group of investigators that includes a scientist now at St. Jude Children's Research Hospital. The investigators developed a model of schizophrenia that provides a way to study and understand how the loss of both PRODH and COMT gene activity contributes to the symptoms of schizophrenia. The insights they gained into the disease with this model are important because the loss of the PRODH gene causes the imbalance in the levels of both glutamate and dopamine; and this imbalance contributes directly to the symptoms of schizophrenia, according to Stanislav Zakharenko, MD, PhD, an assistant member of the Department of Developmental Neurobiology at St. Jude.

Oct-6 protein not a biological marker for schizophrenia

Mon, 24 Oct 2005 14:04:00 PST

The protein Oct-6 is not a biological marker for schizophrenia. The results of a study published today in the open access journal BMC Psychiatry contradict previous findings and show that Oct-6, a protein involved in neurodevelopment, is normally expressed in the adult brain and cannot be used to identify patients with schizophrenia.

BOLDER II (BipOLar DEpRession) study - Quetiapine effective in bipolar depression

Mon, 24 Oct 2005 13:57:00 PST

Newly released top-line results from the BOLDER II (BipOLar DEpRession) study have underlined the potential for SEROQUEL (quetiapine fumarate) in the treatment of patients with major depressive episodes associated with bipolar disorder. In BOLDER II, SEROQUEL 300mg and 600mg doses achieved a statistically significant reduction in levels of bipolar depression compared with placebo (p less than 0.001), as measured by the change from baseline in MADRS* total score.1

CATIE study to guide schizophrenia treatment

Tue, 20 Sep 2005 21:47:00 PST

A large study funded by NIH's National Institute of Mental Health (NIMH) provides, for the first time, detailed information comparing the effectiveness and side effects of five medications both new and older medications that are currently used to treat people with schizophrenia. Overall, the medications were comparably effective but were associated with high rates of discontinuation due to intolerable side effects or failure to adequately control symptoms. Surprisingly, the older, less expensive medication used in the study generally performed as well as the newer medications. The study, which included more than 1,400 people, supplies important new information that will help doctors and patients choose the most appropriate medication according to the patients' individual needs.

CAPON and SchizophreniaDoes Size Matter?

Tue, 13 Sep 2005 16:04:00 PST

Schizophrenia and bipolar disease are complex diseases, with multiple genes and environmental factors thought to be responsible for their manifestation. Many reports have implicated changes in certain regions of the human genome in schizophrenia. An area on Chromosome 1 has been associated with the disease in different studies and populations. Linda Brzustowicz and colleagues had previously described association of several single nucleotide polymorphisms (SNPs) within a gene called CAPON (for carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase) with schizophrenia in a set of Canadian families. A separate study in a Chinese population found an association between schizophrenia and a separate group of SNPs within CAPON. CAPON is an attractive candidate for a schizophrenia gene: CAPON was first identified as a protein binding to neuronal nitric oxide synthase (nNOS), and indirect evidence suggests that it might be linked to the regulation of glutamate neurotransmission. However, so far, no coding sequence mutations in CAPON have been found in patients with schizophrenia.

Dopamine and glutamate hypothesis reconciled

Tue, 13 Sep 2005 04:28:00 PST

Yale School of Medicine researchers published a report this month in the Archives of General Psychiatry that highlights the interplay of two brain signaling systems, glutamate and dopamine, in psychosis and cognitive function.

'Schizophrenia' may not exist

Sat, 10 Sep 2005 15:16:00 PST

Schizophrenia has been attributed to everything from genetic predisposition, brain chemistry, sufferers' home environment and even cat-borne viruses, but no consistent causal pattern has ever been identified. As a result, treatment outcomes for today's patients are not very different from those of patients treated 100 years ago.

Odd behavior and creativity may go hand-in-hand

Wed, 07 Sep 2005 08:13:00 PST

A quirky or socially awkward approach to life might be the key to becoming a great artist, composer or inventor. New research in individuals with schizotypal personalitiespeople characterized by odd behavior and language but who are not psychotic or schizophrenicoffers the first neurological evidence that these individuals are more creative than normal or fully schizophrenic people, and rely more heavily on the right sides of their brains than the general population to access their creativity.

Call for accurate screening of bipolar disorder

Fri, 02 Sep 2005 02:09:00 PST

The British Journal of General Practice (BJGP) has published an editorial paper highlighting the vital role GPs play in distinguishing between unipolar and bipolar disorder and treating it accordingly.

Hope of early diagnostic tool for schizophrenia and bipolar disorder

Thu, 04 Aug 2005 23:50:00 PST

Key research from the University of New South Wales (UNSW) could lead to the first early diagnostic tool for schizophrenia and bipolar disorder.

Discovery of New Dopamine Action May Yield Alternative Psychiatric Drugs

Fri, 29 Jul 2005 15:39:00 PST

Duke University Medical Center researchers have discovered a new mechanism by which chronically high levels of the neurotransmitter dopamine exert their effects on the brain. Normally associated with triggering feelings of pleasure, excess concentrations of dopamine underlie schizophrenia, attention deficit hyperactivity disorder and other psychiatric conditions. The findings therefore provide new research avenues to understand and potentially manage such dopamine-related human disorders, the researchers said.

First study to test antipsychotic on depressive phase

Mon, 04 Jul 2005 13:50:00 PST

For the first time, researchers have demonstrated in separate short-term trials that a single drug therapy may be effective in treating both the manic and depressive phases of bipolar disorder. The condition (bipolar I and II) affects approximately 8 million Americans, who have relied on a combination of drugs to manage their symptoms, and who remain at high risk of committing suicide because of the difficulty in treating the disorder.

Quetiapine effective in reducing aggression & violent behaviour in schizophrenia

Mon, 20 Jun 2005 16:01:00 PST

A new study, published today in the journal Human Psychopharmacology: Clinical and Experimental,1 shows that the atypical antipsychotic SEROQUEL (quetiapine), may be an effective treatment option for patients with schizophrenia who exhibit aggressive behaviour during psychotic episodes.

Research zeros in on bipolar disorder genes

Fri, 17 Jun 2005 03:39:00 PST

Despite an intensive effort, researchers have yet to identify the genes that cause bipolar disorder, yet the practical benefits of such a discovery could reap rich rewards for those suffering from the mental illness.

Schizophrenia is less prevalent than textbook figures

Tue, 31 May 2005 19:02:00 PST

Schizophrenia is a devastating mental illness and a major contributor to the global burden of disease, but how many people are actually suffering from the disease worldwide? John McGrath and colleagues from the University of Queensland have conducted the most comprehensive analysis on the topic and now report their findings in the May issue of the international open-access journal PLoS Medicine.

Quetiapine Improves Cognitive Function in Schizophrenia - Study

Tue, 24 May 2005 12:18:00 PST

Clinical study data showed SEROQUEL improved overall cognitive function in patients with schizophrenia; Database analysis showed greater compliance with atypical antipsychotics

Maternal Exposure to Parasitic Infection may Increase Schizophrenia Risk

Tue, 17 May 2005 18:48:00 PST

A study published last month in the American Journal of Psychiatry suggests an association between maternal exposure to toxoplasmosis and increased risk for developing schizophrenia in adult children.

New Research explain basis of Psychotic Behavior

Mon, 11 Apr 2005 12:47:00 PST

An Oregon Health & Science University researcher is among an international team closing in on why many people with schizophrenia and other psychotic disorders are "supersensitive" to the powerful neurotransmitter dopamine.

Olanzapine prevents Brain Loss in Schizophrenia

Tue, 05 Apr 2005 17:06:00 PST

A new brain imaging study of recently diagnosed schizophrenia patients has found, for the first time, that the loss of gray matter typically experienced by patients can be prevented by one of the new atypical antipsychotic drugs, olanzapine, but not by haloperidol, an older, conventional drug.

DNA microarrays used to detect Bipolar Genes

Thu, 24 Mar 2005 05:34:00 PST

While lithium treatment has proven to be a godsend for many of the two million Americans with bipolar disorder, it is not without its downside. People on the drug may develop hypothyroidism, tremors, cognitive impairment, and excessive thirst and urination and gain weight.

Images of brain activity may hold clues to the onset of schizophrenia

Thu, 17 Mar 2005 19:10:00 PST

A decline in function in the prefrontal cortex, the "executive" or front part of the brain, is present in high-risk individuals experiencing early symptoms of schizophrenia and may reflect biological changes that precede the onset of diagnosable illness, the study indicates.

FDA Approves Aripiprazole for Maintaining Efficacy in Bipolar I Disorder

Mon, 14 Mar 2005 08:50:00 PST

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) approved ABILIFY® (aripiprazole) Tablets and Oral Solution for maintaining efficacy in patients with Bipolar I Disorder with a recent manic or mixed episode who had been stabilized and then maintained for at least six weeks.

Nicotine could have a beneficial effect on the symptoms of schizophrenia

Thu, 03 Mar 2005 18:05:00 PST

Published in the March issue of the British Journal of Psychiatry, the study set out to explore the hypothesis that smoking is a form of 'self-medication' for people with schizophrenia.

Half of people with Bipolar Disorder experienced abuse in childhood

Thu, 10 Feb 2005 17:51:00 PST

Childhood abuse has been associated with many different types of adult psychiatric disorder, including suicidality, substance misuse and dependence, and psychosis. This study set out to examine the prevalence and types of childhood abuse reported by adult patients with bipolar disorder, and to relate them to the complexity of the current illness.

Schizophrenia can be predicted years before development

Fri, 07 Jan 2005 04:42:00 PST

It is possible to predict with some accuracy which people in a high-risk group who will (and will not) develop schizophrenia, some years before the development of the psychosis. The latest publication from the Edinburgh High-Risk Study, which appears in the January 2005 issue of the British Journal of Psychiatry, has shown that among people at increased genetic risk of schizophrenia, a state of vulnerability will occur in many more individuals than will actually develop the disorder.

Painkillers during pregnancy increase risk of schizophrenia by four times

Tue, 02 Nov 2004 15:17:00 PST

Children born to mothers who took analgesics in the second three months of pregnancy run a more than four-fold greater risk of developing schizophrenia, a new study from Denmark has found.

RxPG News : Psychoses

Brain recruiting pattern incorrect in Schizophrenic patients

Schizophrenia Risk Gene DISC1 Plays a Broader Role in the Development of Nervous System

First genome-wide study revealed genetic roots of bipolar illness

Chemical maps hint at drug's effects on schizophrenia

Diagnosis of Major Depression Might Mask Bipolar illness

Intensive psychotherapy more effective than brief therapy for treating bipolar depression

Study challenges idea that schizophrenia is distinct in developing and developed regions

New CATIE Analyses Offer Guidance for Choosing Second-Generation Antipsychotic Medication

New details in schizophrenia treatment trial emerge

Abnormalities in eye movements and attention can predict risk of Schizophrenia

Possible genetic link to schizophrenia identified

Brain scan may help doctors predict schizophrenia

People from broken homes prone to psychotic illnesses

Second-generation antipsychotic medications appear to offer little advantage

Study aims to identify schizophrenics at risk for type 2 diabetes

New Treatment Model for Bipolar Disorder Shows Promise

Effects of ketamine mimic only some of the symptoms of schizophrenia

Association between famine and schizophrenia may yield clues about genetic basis

Neuropeptide S (NPS) may help in treating schizophrenia

Clozapine causes significantly higher rates of metabolic syndrome

Neuropeptide S (NPS) may help in treating schizophrenia

NMDA receptor hypofunction demonstrated in schizophrenia

Altered NRG1-erbB4 signaling may contribute to NMDA receptor hypofunction in schizophrenia

Transcription factor Elk-1's role in neurodegeneration and schizophrenia

Youth with bipolar disorder misread facial expressions as hostile

Schizophrenia limits one's ability to perceive body language

Hospitalized schizophrenics are at a higher risk for developing medical/surgical complications

Transcranial magnetic stimulation to curtail auditory hallucinations in schizophrenia

Brain Changes Indicating Bipolar Disorder Are Not Prominent Until Adulthood

Early Intervention Services in Psychosis Can Achieve Better Outcomes - Study

Manic-depressive illness and the FAT gene

One in five teens needing inpatient psychiatric care may be manic-depressive

Psychosocial Disability Fluctuates Along with Bipolar Symptoms

Loss of PRODH and COMT gene activity linked to schizophrenia

Oct-6 protein not a biological marker for schizophrenia

BOLDER II (BipOLar DEpRession) study - Quetiapine effective in bipolar depression

CATIE study to guide schizophrenia treatment

CAPON and SchizophreniaDoes Size Matter?

Dopamine and glutamate hypothesis reconciled

'Schizophrenia' may not exist

Odd behavior and creativity may go hand-in-hand

Call for accurate screening of bipolar disorder

Hope of early diagnostic tool for schizophrenia and bipolar disorder

Discovery of New Dopamine Action May Yield Alternative Psychiatric Drugs

First study to test antipsychotic on depressive phase

Quetiapine effective in reducing aggression & violent behaviour in schizophrenia

Research zeros in on bipolar disorder genes

Schizophrenia is less prevalent than textbook figures

Quetiapine Improves Cognitive Function in Schizophrenia - Study

Maternal Exposure to Parasitic Infection may Increase Schizophrenia Risk

New Research explain basis of Psychotic Behavior

Olanzapine prevents Brain Loss in Schizophrenia

DNA microarrays used to detect Bipolar Genes

Images of brain activity may hold clues to the onset of schizophrenia

FDA Approves Aripiprazole for Maintaining Efficacy in Bipolar I Disorder

Nicotine could have a beneficial effect on the symptoms of schizophrenia

Half of people with Bipolar Disorder experienced abuse in childhood

Schizophrenia can be predicted years before development

Painkillers during pregnancy increase risk of schizophrenia by four times

CAPON and SchizophreniaDoes Size Matter?